Monday, November 21, 2005

Arimidex After Two Years of Tamoxifen Reduces Recurrence in Post-Menopausal Women

R. Jakesz, et al. The Lancet August 6, 2005
Conclusions: In post-menopausal women with early-stage, hormone-receptor-positive breast cancer, women who switched to Arimidex for three years after taking tamoxifen for two years did better than those taking tamoxifen for five years. Switching reduced the risk of recurrence and the risk of developing a new cancer in the other breast. Women who switched to Arimidex had fewer of the uncommon but serious side effects associated with tamoxifen: endometrial cancer, blood clots, and strokes. But women taking Arimidex had more joint aches and pains and bone fractures. The researchers concluded that five years of tamoxifen is not the best treatment for post-menopausal women with early-stage, hormone-receptor-positive breast cancer. They recommended that women on tamoxifen be switched to Arimidex after two years of tamoxifen treatment.

0 Comments:

Post a Comment

<< Home

/* WebRing Code */